Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 5/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199928 | 0.88 | DHODH (0.62) | EPRS1PTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL116047 | 0.83 | EPRS1 (0.63) | EPRS1PTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL117422 | 0.77 | PTGES (0.84) | EPRS1PTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL116062 | 0.77 | EPRS1 (0.64) | EPRS1PTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL31590457 | 0.74 | PTGES (0.68) | EPRS1PTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL1899018 | 0.73 | PPARA (0.64) | PTGESALDH1A1ALOX5CYP2C9HPGD | |
| SCHEMBL117228 | 0.73 | EPRS1 (0.65) | EPRS1ALDH1A1HSD17B10DHODH | |
| SCHEMBL29788463 | 0.72 | DHODH (0.80) | EPRS1DHODH | |
| SCHEMBL116022 | 0.72 | DHODH (0.80) | EPRS1DHODH | |
| SCHEMBL18320549 | 0.72 | DHODH (0.76) | EPRS1PTGESALDH1A1ALOX5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | EPRS1 13/4885PTGES 1333/4885ALDH1A1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.